{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:34:12Z","timestamp":1793622852680,"version":"4.5.0"},"reference-count":132,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypoxia-inducible factors (HIFs) were discovered as activators of erythropoietin gene transcription in response to reduced oxygen (O2) availability. O2-dependent hydroxylation of HIFs on proline and asparagine residues regulates protein stability and transcriptional activity, respectively. Mutations in genes encoding components of the O2-sensing pathway cause familial erythrocytosis. Several small-molecule inhibitors of HIF prolyl hydroxylases are currently in clinical trials as erythropoiesis-stimulating agents. HIFs are overexpressed in bone marrow neoplasms, and the development of HIF inhibitors may improve outcomes in these disorders.<\/jats:p>","DOI":"10.1182\/blood.2021011043","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T20:07:30Z","timestamp":1629403650000},"page":"2441-2449","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-211X","authenticated-orcid":false,"given":"Gregg L.","family":"Semenza","sequence":"first","affiliation":[{"name":"Department of Genetic Medicine, Department of Pediatrics, Oncology, Department of Medicine, Department of Radiation Oncology, Department of Biological Chemistry, and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2022042115224515500_B1","first-page":"182","article-title":"Red blood cell proteomics update: is there more to discover?","volume":"15","author":"D\u2019Alessandro","year":"2017","journal-title":"Blood Transfus."},{"issue":"3","key":"2022042115224515500_B2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(00)81957-1","article-title":"Perspectives on oxygen sensing","volume":"98","author":"Semenza","year":"1999","journal-title":"Cell."},{"issue":"6005","key":"2022042115224515500_B3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/313806a0","article-title":"Isolation and characterization of genomic and cDNA clones of human erythropoietin","volume":"313","author":"Jacobs","year":"1985","journal-title":"Nature."},{"issue":"22","key":"2022042115224515500_B4","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","article-title":"Cloning and expression of the human erythropoietin gene","volume":"82","author":"Lin","year":"1985","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2022042115224515500_B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med."},{"issue":"24","key":"2022042115224515500_B6","doi-asserted-by":"crossref","first-page":"15563","DOI":"10.1016\/S0021-9258(18)98438-3","article-title":"Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene","volume":"266","author":"Beck","year":"1991","journal-title":"J Biol Chem."},{"issue":"13","key":"2022042115224515500_B7","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022042115224515500_B8","first-page":"842","article-title":"Cloning, sequencing, and evolutionary analysis of the mouse erythropoietin gene","volume":"6","author":"McDonald","year":"1986","journal-title":"Mol Cell Biol."},{"issue":"3","key":"2022042115224515500_B9","first-page":"849","article-title":"Murine erythropoietin gene: cloning, expression, and human gene homology","volume":"6","author":"Shoemaker","year":"1986","journal-title":"Mol Cell Biol."},{"issue":"23","key":"2022042115224515500_B10","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1073\/pnas.88.23.10553","article-title":"Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene","volume":"88","author":"Pugh","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2022042115224515500_B11","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol."},{"issue":"3","key":"2022042115224515500_B12","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J Biol Chem."},{"issue":"12","key":"2022042115224515500_B13","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4 Pt 1","key":"2022042115224515500_B14","doi-asserted-by":"crossref","first-page":"C1172","DOI":"10.1152\/ajpcell.1996.271.4.C1172","article-title":"Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension","volume":"271","author":"Jiang","year":"1996","journal-title":"Am J Physiol."},{"issue":"9","key":"2022042115224515500_B15","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5516","key":"2022042115224515500_B16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science."},{"issue":"5516","key":"2022042115224515500_B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science."},{"issue":"17","key":"2022042115224515500_B18","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1073\/pnas.181341498","article-title":"HIF-1\u03b1 binding to VHL is regulated by stimulus-sensitive proline hydroxylation","volume":"98","author":"Yu","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5414","key":"2022042115224515500_B19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.284.5414.657","article-title":"Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase","volume":"284","author":"Kamura","year":"1999","journal-title":"Science."},{"issue":"6733","key":"2022042115224515500_B20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature."},{"issue":"36","key":"2022042115224515500_B21","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J Biol Chem."},{"issue":"1","key":"2022042115224515500_B22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell."},{"issue":"12","key":"2022042115224515500_B23","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1182\/blood.V82.12.3610.3610","article-title":"Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction","volume":"82","author":"Wang","year":"1993","journal-title":"Blood."},{"issue":"31","key":"2022042115224515500_B24","doi-asserted-by":"crossref","first-page":"19253","DOI":"10.1074\/jbc.272.31.19253","article-title":"Transactivation and inhibitory domains of hypoxia-inducible factor 1\u03b1. Modulation of transcriptional activity by oxygen tension","volume":"272","author":"Jiang","year":"1997","journal-title":"J Biol Chem."},{"issue":"17","key":"2022042115224515500_B25","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1074\/jbc.272.17.11205","article-title":"Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit","volume":"272","author":"Pugh","year":"1997","journal-title":"J Biol Chem."},{"issue":"20","key":"2022042115224515500_B26","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev."},{"issue":"12","key":"2022042115224515500_B27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev."},{"issue":"Pt 3","key":"2022042115224515500_B28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/bj20021162","article-title":"Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the \u03b2-carbon of asparagine-803","volume":"367","author":"McNeill","year":"2002","journal-title":"Biochem J."},{"key":"2022042115224515500_B29","doi-asserted-by":"crossref","first-page":"e31176","DOI":"10.7554\/eLife.31176","article-title":"The last common ancestor of animals lacked the HIF pathway and respired in low-oxygen environments","volume":"7","author":"Mills","year":"2018","journal-title":"eLife."},{"issue":"13","key":"2022042115224515500_B30","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1074\/jbc.272.13.8581","article-title":"Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway","volume":"272","author":"Hogenesch","year":"1997","journal-title":"J Biol Chem."},{"issue":"36","key":"2022042115224515500_B31","doi-asserted-by":"crossref","first-page":"32405","DOI":"10.1074\/jbc.C200328200","article-title":"Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3\u03b1 locus","volume":"277","author":"Makino","year":"2002","journal-title":"J Biol Chem."},{"issue":"1","key":"2022042115224515500_B32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev."},{"issue":"10","key":"2022042115224515500_B33","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1073\/pnas.90.10.4495","article-title":"Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis","volume":"90","author":"de la Chapelle","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2022042115224515500_B34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.V86.1.15.bloodjournal86115","article-title":"Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin","volume":"86","author":"Sokol","year":"1995","journal-title":"Blood."},{"issue":"12","key":"2022042115224515500_B35","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1182\/blood.V89.12.4628","article-title":"Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene","volume":"89","author":"Arcasoy","year":"1997","journal-title":"Blood."},{"issue":"10","key":"2022042115224515500_B36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1709064","article-title":"A gain-of-function mutation in EPO in familial erythrocytosis","volume":"378","author":"Zmajkovic","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2022042115224515500_B37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat Genet."},{"issue":"6","key":"2022042115224515500_B38","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V89.6.2148","article-title":"Congenital polycythemia in Chuvashia","volume":"89","author":"Sergeyeva","year":"1997","journal-title":"Blood."},{"issue":"7","key":"2022042115224515500_B39","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1371\/journal.pmed.0030290","article-title":"Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology","volume":"3","author":"Smith","year":"2006","journal-title":"PLoS Med."},{"issue":"28","key":"2022042115224515500_B40","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.1073\/pnas.1002339107","article-title":"Regulation of human metabolism by hypoxia-inducible factor","volume":"107","author":"Formenti","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2022042115224515500_B41","first-page":"3879","article-title":"von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2\u03b1 signaling and splenic erythropoiesis","volume":"117","author":"Hickey","year":"2007","journal-title":"J Clin Invest."},{"issue":"10","key":"2022042115224515500_B42","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2003-07-2535","article-title":"Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors","volume":"103","author":"Gordeuk","year":"2004","journal-title":"Blood."},{"issue":"3","key":"2022042115224515500_B43","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.3324\/haematol.2019.216267","article-title":"Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit","volume":"105","author":"Gordeuk","year":"2020","journal-title":"Haematologica."},{"issue":"19","key":"2022042115224515500_B44","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2012-11-469296","article-title":"Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer","volume":"121","author":"Lanikova","year":"2013","journal-title":"Blood."},{"issue":"11","key":"2022042115224515500_B45","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/pbc.25056","article-title":"The homozygous VHL(D126N) missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension","volume":"61","author":"Sarangi","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"2022042115224515500_B46","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.2012.070508","article-title":"The phenotype of polycythemia due to Croatian homozygous VHL (571C&gt;G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C&gt;T:R200W)","volume":"98","author":"Tomasic","year":"2013","journal-title":"Haematologica."},{"key":"2022042115224515500_B47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","article-title":"Von Hippel-Lindau disease","volume":"2","author":"Kaelin","year":"2007","journal-title":"Annu Rev Pathol."},{"issue":"6","key":"2022042115224515500_B48","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2007-04-084434","article-title":"A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove","volume":"110","author":"Percy","year":"2007","journal-title":"Blood."},{"issue":"3","key":"2022042115224515500_B49","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022042115224515500_B50","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.1016\/j.blre.2019.100590","article-title":"Update on mutations in the HIF: EPO pathway and their role in erythrocytosis","volume":"37","author":"Lappin","year":"2019","journal-title":"Blood Rev."},{"issue":"25","key":"2022042115224515500_B51","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"2022042115224515500_B52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J Mol Med (Berl)."},{"issue":"2","key":"2022042115224515500_B53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMoa073123","article-title":"A gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N Engl J Med."},{"issue":"10","key":"2022042115224515500_B54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med."},{"issue":"6","key":"2022042115224515500_B55","doi-asserted-by":"crossref","first-page":"e1787","DOI":"10.1542\/peds.2013-2419","article-title":"Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male","volume":"133","author":"Toyoda","year":"2014","journal-title":"Pediatrics."},{"issue":"4","key":"2022042115224515500_B56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med (Berl)."},{"issue":"6","key":"2022042115224515500_B57","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1096\/fj.10-177378","article-title":"Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2\u03b1 gain-of-function mutation","volume":"25","author":"Formenti","year":"2011","journal-title":"FASEB J."},{"issue":"7","key":"2022042115224515500_B58","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0608382104","article-title":"Acute postnatal ablation of Hif-2\u03b1 results in anemia","volume":"104","author":"Gruber","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2022042115224515500_B59","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1172\/JCI5912","article-title":"Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1\u03b1","volume":"103","author":"Yu","year":"1999","journal-title":"J Clin Invest."},{"issue":"10","key":"2022042115224515500_B60","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI15496","article-title":"Heterozygous deficiency of hypoxia-inducible factor-2\u03b1 protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia","volume":"111","author":"Brusselmans","year":"2003","journal-title":"J Clin Invest."},{"key":"2022042115224515500_B61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev-genom-111119-073356","article-title":"The genomics and genetics of oxygen homeostasis","volume":"21","author":"Semenza","year":"2020","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"11","key":"2022042115224515500_B62","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"issue":"11","key":"2022042115224515500_B63","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"issue":"17","key":"2022042115224515500_B64","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med."},{"issue":"17","key":"2022042115224515500_B65","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med."},{"issue":"32","key":"2022042115224515500_B66","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J Biol Chem."},{"issue":"28","key":"2022042115224515500_B67","doi-asserted-by":"crossref","first-page":"21048","DOI":"10.1074\/jbc.M000636200","article-title":"Role of hypoxia-inducible factor 1 in transcriptional activation of ceruloplasmin by iron deficiency","volume":"275","author":"Mukhopadhyay","year":"2000","journal-title":"J Biol Chem."},{"issue":"5","key":"2022042115224515500_B68","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2\u03b1, but not HIF-1\u03b1, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J Clin Invest."},{"issue":"2","key":"2022042115224515500_B69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab."},{"issue":"7","key":"2022042115224515500_B70","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology."},{"issue":"7","key":"2022042115224515500_B71","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism [published correction appears in Nat Genet. 2020;52(4):463]","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet."},{"issue":"1","key":"2022042115224515500_B72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.kint.2021.03.019","article-title":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","volume":"100","author":"Hanudel","year":"2021","journal-title":"Kidney Int."},{"issue":"2","key":"2022042115224515500_B73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cmet.2013.01.007","article-title":"The IRP1-HIF-2\u03b1 axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption","volume":"17","author":"Anderson","year":"2013","journal-title":"Cell Metab."},{"issue":"2","key":"2022042115224515500_B74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cmet.2012.12.016","article-title":"Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2\u03b1","volume":"17","author":"Ghosh","year":"2013","journal-title":"Cell Metab."},{"issue":"11","key":"2022042115224515500_B75","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1056\/NEJMe1908978","article-title":"Roxadustat and anemia of chronic kidney disease","volume":"381","author":"Kaplan","year":"2019","journal-title":"N Engl J Med."},{"issue":"8","key":"2022042115224515500_B76","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"2022042115224515500_B77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MNH.0000000000000617","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease","volume":"29","author":"Kurata","year":"2020","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"1","key":"2022042115224515500_B78","doi-asserted-by":"crossref","first-page":"e13668","DOI":"10.1111\/apha.13668","article-title":"Pharmacological HIF-PHD inhibition reduces renovascular resistance and increases glomerular filtration by stimulating nitric oxide generation","volume":"233","author":"Burmakin","year":"2021","journal-title":"Acta Physiol (Oxf)."},{"issue":"5","key":"2022042115224515500_B79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene."},{"key":"2022042115224515500_B80","article-title":"Targeting hypoxia-inducible factor 1 for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds [published online ahead of print 28 September 2020]","author":"Ma","journal-title":"Semin Cancer Biol."},{"issue":"9","key":"2022042115224515500_B81","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/cells8091083","article-title":"Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges","volume":"8","author":"Noman","year":"2019","journal-title":"Cells."},{"issue":"12","key":"2022042115224515500_B82","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-inducible factors: master regulators of cancer progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer."},{"key":"2022042115224515500_B83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-030-34461-0_21","article-title":"Fatal alliance of hypoxia-\/HIF-1\u03b1-driven microenvironmental traits promoting cancer progression","volume":"1232","author":"Vaupel","year":"2020","journal-title":"Adv Exp Med Biol."},{"key":"2022042115224515500_B84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.acr.2018.11.001","article-title":"Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy","volume":"141","author":"Xiang","year":"2019","journal-title":"Adv Cancer Res."},{"issue":"6","key":"2022042115224515500_B85","first-page":"1541","article-title":"Modulation of hypoxia-inducible factor 1\u03b1 expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics","volume":"60","author":"Zhong","year":"2000","journal-title":"Cancer Res."},{"issue":"12","key":"2022042115224515500_B86","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","article-title":"HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression","volume":"21","author":"Laughner","year":"2001","journal-title":"Mol Cell Biol."},{"issue":"42","key":"2022042115224515500_B87","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1073\/pnas.0909353106","article-title":"Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization","volume":"106","author":"Lee","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"2022042115224515500_B88","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00109-011-0855-y","article-title":"Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis","volume":"90","author":"Wong","year":"2012","journal-title":"J Mol Med (Berl)."},{"issue":"9","key":"2022042115224515500_B89","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol Cell Biol."},{"issue":"5","key":"2022042115224515500_B90","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2403332","article-title":"Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF [published correction appears in Leukemia. 2004;18(6):1164]","volume":"18","author":"Wellmann","year":"2004","journal-title":"Leukemia."},{"issue":"10","key":"2022042115224515500_B91","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/cbt.20838","article-title":"Regulation of HIF-1\u03b1 signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment","volume":"13","author":"Frolova","year":"2012","journal-title":"Cancer Biol Ther."},{"issue":"25","key":"2022042115224515500_B92","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2014-10-609370","article-title":"Leukemia stem cells in T-ALL require active Hif1\u03b1 and Wnt signaling","volume":"125","author":"Giambra","year":"2015","journal-title":"Blood."},{"issue":"7104","key":"2022042115224515500_B93","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nature05029","article-title":"PML inhibits HIF-1\u03b1 translation and neoangiogenesis through repression of mTOR","volume":"442","author":"Bernardi","year":"2006","journal-title":"Nature."},{"issue":"10","key":"2022042115224515500_B94","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3324\/haematol.13096","article-title":"Accumulation of hypoxia-inducible factor-1 \u03b1 protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic\u00a0acid","volume":"93","author":"Zhang","year":"2008","journal-title":"Haematologica."},{"issue":"16","key":"2022042115224515500_B95","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1158\/1078-0432.CCR-14-3022","article-title":"Synergistic leukemia eradication by combined treatment with retinoic acid and HIF inhibition by EZN-2208 (PEG-SN38) in preclinical models of PML-RAR\u03b1 and PLZF-RAR\u03b1-driven leukemia","volume":"21","author":"Coltella","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"22","key":"2022042115224515500_B96","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1182\/blood-2008-10-185686","article-title":"Aberrant regulation of pVHL levels by microRNA promotes the HIF\/VEGF axis in\u00a0CLL B cells","volume":"113","author":"Ghosh","year":"2009","journal-title":"Blood."},{"issue":"16","key":"2022042115224515500_B97","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2015-07-657056","article-title":"HIF-1\u03b1 regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment","volume":"127","author":"Valsecchi","year":"2016","journal-title":"Blood."},{"key":"2022042115224515500_B98","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2016.11.014","article-title":"mRNA overexpression of the hypoxia inducible factor 1 \u03b1 subunit gene (HIF1A): an independent predictor of poor overall survival in chronic lymphocytic leukemia","volume":"53","author":"Kontos","year":"2017","journal-title":"Leuk Res."},{"issue":"4","key":"2022042115224515500_B99","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3324\/haematol.2019.217430","article-title":"HIF-1\u03b1 is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia","volume":"105","author":"Griggio","year":"2020","journal-title":"Haematologica."},{"issue":"10","key":"2022042115224515500_B100","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1\u03b1, through a pathway involving phosphoinositide 3-kinase and the mammalian target of\u00a0rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood."},{"issue":"20","key":"2022042115224515500_B101","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1\u03b1-induced metabolic reprograming","volume":"29","author":"Zhao","year":"2010","journal-title":"Oncogene."},{"issue":"11","key":"2022042115224515500_B102","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood."},{"issue":"21","key":"2022042115224515500_B103","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood."},{"issue":"5","key":"2022042115224515500_B104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022042115224515500_B105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2005-03-1278","article-title":"Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia","volume":"107","author":"Liu","year":"2006","journal-title":"Blood."},{"issue":"6","key":"2022042115224515500_B106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.onc.1210676","article-title":"Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1\u03b1","volume":"27","author":"Peng","year":"2008","journal-title":"Oncogene."},{"issue":"24","key":"2022042115224515500_B107","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2014-04-567065","article-title":"HIF-1\u03b1 can act as a tumor suppressor gene in murine acute myeloid leukemia","volume":"124","author":"Velasco-Hernandez","year":"2014","journal-title":"Blood."},{"issue":"5","key":"2022042115224515500_B108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2010.10.020","article-title":"Hypoxia-inducible factor-1\u03b1 protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia","volume":"35","author":"Deeb","year":"2011","journal-title":"Leuk Res."},{"issue":"8","key":"2022042115224515500_B109","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2015.56","article-title":"AML1\/ETO cooperates with HIF1\u03b1 to promote leukemogenesis through DNMT3a transactivation","volume":"29","author":"Gao","year":"2015","journal-title":"Leukemia."},{"issue":"3","key":"2022042115224515500_B110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbrc.2009.10.094","article-title":"FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression","volume":"390","author":"Jin","year":"2009","journal-title":"Biochem Biophys Res Commun."},{"issue":"8","key":"2022042115224515500_B111","doi-asserted-by":"crossref","first-page":"e23108","DOI":"10.1371\/journal.pone.0023108","article-title":"Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104","volume":"6","author":"Benito","year":"2011","journal-title":"PLoS One."},{"issue":"21","key":"2022042115224515500_B112","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1182\/blood-2011-11-389957","article-title":"Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment","volume":"119","author":"Chen","year":"2012","journal-title":"Blood."},{"issue":"13","key":"2022042115224515500_B113","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022042115224515500_B114","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","article-title":"Regulation of the HIF-1\u03b1 level is essential for hematopoietic stem cells","volume":"7","author":"Takubo","year":"2010","journal-title":"Cell Stem Cell."},{"issue":"6","key":"2022042115224515500_B115","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/j.leukres.2012.02.028","article-title":"Elevated HIF-1\u03b1 expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy","volume":"36","author":"Matsunaga","year":"2012","journal-title":"Leuk Res."},{"issue":"4","key":"2022042115224515500_B116","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.stem.2011.02.006","article-title":"Targeting HIF1\u03b1 eliminates cancer stem cells in hematological malignancies","volume":"8","author":"Wang","year":"2011","journal-title":"Cell Stem Cell."},{"issue":"7","key":"2022042115224515500_B117","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1182\/blood-2013-12-544221","article-title":"Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood."},{"issue":"13","key":"2022042115224515500_B118","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1084\/jem.20150452","article-title":"Hif-1\u03b1 and Hif-2\u03b1 synergize to suppress AML development but are dispensable for disease maintenance","volume":"212","author":"Vukovic","year":"2015","journal-title":"J Exp Med."},{"issue":"7","key":"2022042115224515500_B119","first-page":"2831","article-title":"Hypoxia and activated VEGF\/receptor pathway in multiple myeloma","volume":"30","author":"Giatromanolaki","year":"2010","journal-title":"Anticancer Res."},{"issue":"5","key":"2022042115224515500_B120","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3324\/haematol.2009.015628","article-title":"Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells","volume":"95","author":"Martin","year":"2010","journal-title":"Haematologica."},{"issue":"11","key":"2022042115224515500_B121","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/leu.2010.193","article-title":"Low bone marrow oxygen tension and hypoxia-inducible factor-1\u03b1 overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells","volume":"24","author":"Colla","year":"2010","journal-title":"Leukemia."},{"issue":"15","key":"2022042115224515500_B122","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1128\/MCB.00552-06","article-title":"Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1\u03b1 C-terminal activation domain","volume":"26","author":"Kaluz","year":"2006","journal-title":"Mol Cell Biol."},{"issue":"6","key":"2022042115224515500_B123","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Shin","year":"2008","journal-title":"Blood."},{"issue":"12","key":"2022042115224515500_B124","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/0008-5472.CAN-08-4603","article-title":"Targeting angiogenesis via a c-Myc\/hypoxia-inducible factor-1\u03b1-dependent pathway in multiple myeloma","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res."},{"key":"2022042115224515500_B125","doi-asserted-by":"crossref","first-page":"27280","DOI":"10.1038\/srep27280","article-title":"HIF-1\u03b1 and HIF-2\u03b1 induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide","volume":"6","author":"Feng","year":"2016","journal-title":"Sci Rep."},{"issue":"8","key":"2022042115224515500_B126","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2013.24","article-title":"Hypoxia-inducible factor (HIF)-1\u03b1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction","volume":"27","author":"Storti","year":"2013","journal-title":"Leukemia."},{"issue":"19","key":"2022042115224515500_B127","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med."},{"issue":"5","key":"2022042115224515500_B128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"2022042115224515500_B129","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/2159-8290.CD-17-1203","article-title":"Pathobiological pseudohypoxia as a putative mechanism underlying myelodysplastic syndromes","volume":"8","author":"Hayashi","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"2022042115224515500_B130","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41375-019-0629-z","article-title":"Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms","volume":"34","author":"Baumeister","year":"2020","journal-title":"Leukemia."},{"issue":"6","key":"2022042115224515500_B131","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","article-title":"Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"4","author":"Gangaraju","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"2022042115224515500_B132","doi-asserted-by":"crossref","first-page":"802-","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/16\/2441\/1892592\/bloodbld2021011043c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/16\/2441\/1892592\/bloodbld2021011043c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:39:32Z","timestamp":1650555572000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/16\/2441\/476633\/Breakthrough-science-hypoxia-inducible-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":132,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,4,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011043","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}